Endometriosis - Pipeline Review, H2 2015

Published: October 2015
No. of Pages: 131
   

Global Markets Direct’s, ‘Endometriosis Pipeline Review, H2 2015’, provides an overview of the Endometriosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Endometriosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometriosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope


  • The report provides a snapshot of the global therapeutic landscape of Endometriosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Endometriosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Endometriosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Endometriosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy


  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Endometriosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Endometriosis - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Endometriosis Overview 8
Therapeutics Development 9
Pipeline Products for Endometriosis - Overview 9
Pipeline Products for Endometriosis - Comparative Analysis 10
Endometriosis - Therapeutics under Development by Companies 11
Endometriosis - Therapeutics under Investigation by Universities/Institutes 13
Endometriosis - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Endometriosis - Products under Development by Companies 18
Endometriosis - Products under Investigation by Universities/Institutes 20
Endometriosis - Companies Involved in Therapeutics Development 21
AbbVie Inc. 21
Addex Therapeutics Ltd 22
APAvadis Biotechnologies Srl 23
Astellas Pharma Inc. 24
Bayer AG 25
Dongkook Pharmaceutical Co., Ltd. 26
ElexoPharm GmbH 27
EndoCeutics, Inc. 28
Enteris BioPharma, Inc. 29
Euroscreen S.A. 30
Evotec AG 31
Forendo Pharma Oy 32
GlaxoSmithKline Plc 33
Kissei Pharmaceutical Co., Ltd. 34
Lipicard Technologies Limited 35
Nippon Shinyaku Co., Ltd. 36
Orphagen Pharmaceuticals, Inc. 37
Philogen S.p.A. 38
Repros Therapeutics Inc. 39
SK Chemicals Co., Ltd. 40
Takeda Pharmaceutical Company Limited 41
ValiRx Plc 42
Endometriosis - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Combination Products 44
Assessment by Target 45
Assessment by Mechanism of Action 48
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
(anastrozole + levonorgestrel) - Drug Profile 54
acolbifene hydrochloride + prasterone + GnRH agonist - Drug Profile 55
ADX-68692 - Drug Profile 56
ASP-1707 - Drug Profile 57
BAY-1128688 - Drug Profile 58
bentamapimod - Drug Profile 59
Drug to Inhibit C-Jun for Endometriosis - Drug Profile 61
Drugs for Endometriosis - Drug Profile 62
Drugs for Endometriosis and Uterine Fibroids - Drug Profile 63
elagolix sodium - Drug Profile 64
epelsiban besylate - Drug Profile 66
ESN-364 - Drug Profile 68
EVE-104 - Drug Profile 69
FP-5677 - Drug Profile 70
goserelin - Drug Profile 71
KLH-2109 - Drug Profile 72
leuprolide acetate - Drug Profile 73
LT-6121 - Drug Profile 74
Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis - Drug Profile 75
NCE-403 - Drug Profile 76
NS-580 - Drug Profile 77
Peptides for Cancer and Endometriosis - Drug Profile 78
Peptides to Inhibit Aminopeptidase A for Cancer and Endometriosis - Drug Profile 79
PGL-2001 - Drug Profile 80
Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome - Drug Profile 81
relugolix - Drug Profile 82
Small Molecule to Antagonize FSH Receptor for Women''s Health - Drug Profile 83
Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile 84
Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile 85
Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing''s Disease - Drug Profile 86
Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile 87
Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile 88
Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile 89
SR-16234 - Drug Profile 90
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 91
telapristone acetate - Drug Profile 92
Tetravil - Drug Profile 95
triptorelin pamoate - Drug Profile 97
VAL-201 - Drug Profile 98
vilaprisan - Drug Profile 100
VPE-001 - Drug Profile 101
VPEA-004 - Drug Profile 102
Endometriosis - Recent Pipeline Updates 103
Endometriosis - Dormant Projects 117
Endometriosis - Discontinued Products 119
Endometriosis - Product Development Milestones 120
Featured News & Press Releases 120
Appendix 127
Methodology 127
Coverage 127
Secondary Research 127
Primary Research 127
Expert Panel Validation 127
Contact Us 127
Disclaimer 128

List of Tables

Number of Products under Development for Endometriosis, H2 2015 12
Number of Products under Development for Endometriosis - Comparative Analysis, H2 2015 13
Number of Products under Development by Companies, H2 2015 15
Number of Products under Investigation by Universities/Institutes, H2 2015 16
Comparative Analysis by Late Stage Development, H2 2015 17
Comparative Analysis by Clinical Stage Development, H2 2015 18
Comparative Analysis by Early Stage Development, H2 2015 19
Comparative Analysis by Unknown Stage Development, H2 2015 20
Products under Development by Companies, H2 2015 21
Products under Development by Companies, H2 2015 (Contd..1) 22
Products under Investigation by Universities/Institutes, H2 2015 23
Endometriosis - Pipeline by AbbVie Inc., H2 2015 24
Endometriosis - Pipeline by Addex Therapeutics Ltd, H2 2015 25
Endometriosis - Pipeline by APAvadis Biotechnologies Srl, H2 2015 26
Endometriosis - Pipeline by Astellas Pharma Inc., H2 2015 27
Endometriosis - Pipeline by Bayer AG, H2 2015 28
Endometriosis - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2015 29
Endometriosis - Pipeline by ElexoPharm GmbH, H2 2015 30
Endometriosis - Pipeline by EndoCeutics, Inc., H2 2015 31
Endometriosis - Pipeline by Enteris BioPharma, Inc., H2 2015 32
Endometriosis - Pipeline by Euroscreen S.A., H2 2015 33
Endometriosis - Pipeline by Evotec AG, H2 2015 34
Endometriosis - Pipeline by Forendo Pharma Oy, H2 2015 35
Endometriosis - Pipeline by GlaxoSmithKline Plc, H2 2015 36
Endometriosis - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2015 37
Endometriosis - Pipeline by Lipicard Technologies Limited, H2 2015 38
Endometriosis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015 39
Endometriosis - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2015 40
Endometriosis - Pipeline by Philogen S.p.A., H2 2015 41
Endometriosis - Pipeline by Repros Therapeutics Inc., H2 2015 42
Endometriosis - Pipeline by SK Chemicals Co., Ltd., H2 2015 43
Endometriosis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 44
Endometriosis - Pipeline by ValiRx Plc, H2 2015 45
Assessment by Monotherapy Products, H2 2015 46
Assessment by Combination Products, H2 2015 47
Number of Products by Stage and Target, H2 2015 49
Number of Products by Stage and Mechanism of Action, H2 2015 52
Number of Products by Stage and Route of Administration, H2 2015 54
Number of Products by Stage and Molecule Type, H2 2015 56
Endometriosis Therapeutics - Recent Pipeline Updates, H2 2015 106
Endometriosis - Dormant Projects, H2 2015 120
Endometriosis - Dormant Projects (Contd..1), H2 2015 121
Endometriosis - Discontinued Products, H2 2015 122

List of Figures

Number of Products under Development for Endometriosis, H2 2015 12
Number of Products under Development for Endometriosis - Comparative Analysis, H2 2015 13
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 16
Comparative Analysis by Clinical Stage Development, H2 2015 18
Comparative Analysis by Early Stage Products, H2 2015 19
Assessment by Monotherapy Products, H2 2015 46
Assessment by Combination Products, H2 2015 47
Number of Products by Top 10 Targets, H2 2015 48
Number of Products by Stage and Top 10 Targets, H2 2015 48
Number of Products by Top 10 Mechanism of Actions, H2 2015 51
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 51
Number of Products by Top 10 Routes of Administration, H2 2015 53
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 53
Number of Products by Top 10 Molecule Types, H2 2015 55
Number of Products by Stage and Top 10 Molecule Types, H2 2015 55

Published By: Global Markets Direct
Product Code: Global Markets Direct13300


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we�ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: